Cerus Corporation revised revenue guidance for the year 2023. The company is adjusting its previously stated product revenue guidance range. The company expected full-year 2023 product revenue will be in the range of $160 million to $165 million, compared to its previous range of $165 million to $170 million, due to a temporary reduction in the U.S. platelet kit shelf life, a reduction in platelet collections in parts of Europe, and new Russia sanctions instituted during the quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.91 USD | +1.60% | +8.52% | -11.57% |
05-02 | Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024 | |
05-02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.57% | 348M | |
+10.49% | 125B | |
-7.14% | 10.97B | |
+4.05% | 8.99B | |
+35.39% | 5.38B | |
-14.29% | 4.86B | |
+8.31% | 3.43B | |
-8.87% | 2.78B | |
-4.33% | 2.22B | |
-0.90% | 2.21B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Revises Revenue Guidance for the Year 2023